- Home
- ALLO vs EVAC Comparison
ALLO vs EVAC Comparison
Compare ALLO & EVAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
Current Price
$2.09
N/A
Current Price
$10.27
Company Overview
Basic Information| Metric | ALLO | EVAC |
|---|---|---|
| Founded | 2017 | 2024 |
| Country | United States | United States |
| Employees | 152 | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Fluid Controls |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 722.1M | 592.7M |
| IPO Year | 2018 | 2025 |
Fundamental Metrics
Financial Performance| Metric | ALLO | EVAC |
|---|---|---|
| Price | $2.09 | $10.27 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 15 | 0 |
| Target Price | ★ $8.35 | N/A |
| AVG Volume (30 Days) | ★ 5.9M | 48.5K |
| Earning Date | 05-07-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 34.09 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $142,416.42 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.04 | $9.90 |
| 52 Week High | $4.46 | $10.30 |
Technical Indicators
Market Signals| Indicator | ALLO | EVAC |
|---|---|---|
| Relative Strength Index (RSI) | 54.73 | 57.03 |
| Support Level | $2.07 | $10.16 |
| Resistance Level | $2.25 | $10.29 |
| Average True Range (ATR) | 0.11 | 0.01 |
| MACD | 0.02 | -0.00 |
| Stochastic Oscillator | 65.85 | 50.00 |
Price Performance
Historical Comparison ALLO
EVAC
About ALLO Allogene Therapeutics Inc.
Allogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. Its pipeline includes "off-the-shelf" T cell candidates designed to target cancer cells or eliminate autoreactive cells in patients with autoimmune disorders. Its three core programs are: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID) and Renal Cell Carcinoma (RCC).
About EVAC EQV Ventures Acquisition Corp. II Class A Ordinary Shares
EQV Ventures Acquisition Corp II is a blank check company.